To determine the therapeutic benefit of TLR9-agonist CpG-ODN in LAM disease, we performed survival studies comparing the effect of two doses of intranasal using our metastatic mouse model of LAM. This evidence concerns the gene TLR9 and lymphangioleiomyomatosis.